Metastatic Hormone-Sensitive Prostate Cancer

FDA Begins Priority Review of Xtandi, a Drug Candidate for Metastatic Hormone-Sensitive Prostate Cancer

Post author:Scott Carlson
Post published:September 3, 2019
Post category:Cancer

According to a press release from American pharmaceutical giant Pfizer, Inc. the FDA recently agreed to review a supplemental New Drug Application for Xtandi. Xtandi was first approved for the…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More